[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angioedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angioedema":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,90,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100388150","deployment-o-the-multidisciplinary-prospective-cohort-imminent-100388150",false,"NCT04334031","Deployment o the Multidisciplinary Prospective Cohort Imminent","IMMINeNT","Inclusion Criteria:\n\n* Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)\n* Social insured\n* Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.\n\nExclusion Criteria:\n\n* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system.\n* Pregnant or breastfeeding woman\n* Persons deprived of liberty\n* Protected minors or adults\n* Persons who have refused or are incapable of giving informed consent\n* Persons in Emergency Situations","ALL","18 Years",{"count":19,"type":20},2200,"ESTIMATED","INTERVENTIONAL",[23],"NA","Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.\n\nBeyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as \"targeted therapies\". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.\n\nThese similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.",[26,27,28,29,30,31,32,33,34],"Chronic Inflammatory Disease","Angioedema","Severe Asthma","Lupus","Atopic Dermatitis","Psoriatic Arthritis","Multiple Sclerosis","Systemic Sclerosis","Behçet Disease",[36,37,38,39,40],"Immune Mediated Inflammatory Diseases (IMIDs)","biomarker","cohort study","quality of life","disease severity","RECRUITING","2026-04-28",{"date":44,"type":45},"2026-05-05","ACTUAL",{"date":47,"type":45},"2020-07-20",{"date":49,"type":20},"2031-07-21",{"name":51,"class":52},"University Hospital, Lille","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":53},"100596541","phase-1-oral-deucrictibant-for-prophylactic-and-acute-treatment-in-hereditary-angioedema-patients-100596541","NCT07046806","Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients","Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)","BK-AE-nC1INH","Inclusion Criteria:\n\n1. Provision of written informed consent.\n2. Male or female, aged ≥18 at the time of provision of informed consent.\n3. Diagnosis of bradykinin-mediated angioedema based upon all of the following:\n\n   * Clinical history consistent with angioedema (subcutaneous or mucosal, nonpruritic swelling without accompanying urticaria), not responsive to treatments of anti-histamine, corticosteroid, and\u002For omalizumab.\n   * Tried and failed at least 2 weeks of cetirizine 20 mg twice a day (or its equivalent alternative antihistamines, such as fexofenadine, loratadine, desloratadine or levocetirizine, etc.).\n   * Total blood BK peptide levels following 3 days cold activation is above the diagnostic value in non-attack and\u002For attack period\\*.\n\n     \\*The \"attack period\" is defined as within 24 hours after an attack.\n   * Documented diagnostic testing results: C1INH antigen concentration and functional activity within normal range; C4 antigen concentration within normal range.\n4. Documented history of at least 2 angioedema attacks in the previous 2 months.\n5. Reliable access and experience to use standard of care medication to effectively manage acute angioedema attacks.\n\nExclusion Criteria:\n\n1. Any diagnosis of angioedema other than BK-AE-nC1INH.\n2. Participation in a clinical study with any other investigational drug within the previous 30 days or within 5 half-lives of the investigational drug at Screening (whichever was longer).\n3. Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptives or hormonal replacement therapy) within 4 weeks of Screening.\n4. Receiving prophylactic treatment for BK-AE-nC1INH. Participants who have previously received prophylactic therapy but have stopped can participate in this study provided a sufficiently long washout period (≥5 half-life) is observed before the participant is screened. Exclusion includes use of:\n\n   • Short-term prophylaxis for BK-AE-nC1INH within 7 days prior to Screening.\n5. Any females who are pregnant, plan to become pregnant, or are currently breast-feeding.\n6. Abnormal hepatic function (aspartate aminotransferase \\>2× upper limit of normal, alanine aminotransferase \\>2× ULN, or total bilirubin \\>1.5× upper limit of normal). Participants with Gilbert's syndrome, defined as isolated increase of total bilirubin ≤3× upper limit of normal and aspartate aminotransferase and alanine aminotransferase within the normal range, are not excluded.\n7. Abnormal renal function (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n8. Any clinically significant history of angina, myocardial infarction, syncope, stroke, left ventricular hypertrophy or cardiomyopathy, uncontrolled hypertension, bradycardia, or any other clinically significant cardiovascular abnormality within the previous year that, in the opinion of the Investigator, would interfere with the participant's safety or ability to participate in the study.\n9. History of epilepsy and other significant neurological diseases.\n10. Any clinically significant gastrointestinal dysfunction (eg, diarrhea, inflammatory bowel disease) which may impact on study drug absorption.\n11. History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse.\n12. Use of concomitant medications with systemic absorption that are moderate and strong inhibitors or strong inducers of CYP3A4, such as clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, and grapefruit juice as well as carbamazepine, and rifampin within the last 30◦days or within 5◦half-lives (whichever is longer) of the time of randomization.\n13. Known hypersensitivity to deucrictibant or any of the excipients of study drug.","75 Years",{"count":64,"type":20},10,[66,67],"PHASE1","PHASE2","To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.",[70,27,71,72],"Hereditary Angioedema (HAE)","Bradykinin-mediated Angioedema","C1 Inhibitor Deficiency",[74,75,76,60,77,78,79],"Bradykinin","deucrictibant","HAE","nC1INH","C1 Inhibitor","C4","2025-06-23",{"date":82,"type":45},"2025-07-02",{"date":84,"type":45},"2025-03-10",{"date":86,"type":20},"2026-04-01",{"name":88,"class":89},"Institute for Asthma and Allergy","NETWORK",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":53},"100578990","phase-4-lanadelumab-in-long-term-prophylaxis-of-acquired-angioedema-100578990","NCT06818474","Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","Inclusion Criteria:\n\n* A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and\u002For paraproteinemia (e.g. monoclonal gammopathy of unknown significance)\n* historical attack rate of \\>= on attack per month prior to starting tranexamic acid (TAA)\n\nExclusion Criteria:\n\n* History of anaphylaxis or hypersensitivity to biologics\n* History of major systemic disease not well controlled in opinion of the PI\n* Women who are pregnant or breast feeding\n* Concurrent participation in other clinical trials\n* HAE Type 1 or 2 and normal complement HAE",{"count":97,"type":20},5,[99],"PHASE4","use of lanadelumab in patients with acquired angioedema",[27],"2025-02-24",{"date":104,"type":45},"2025-02-25",{"date":106,"type":45},"2024-06-01",{"date":108,"type":20},"2027-12-01",{"name":110,"class":52},"Bernstein Clinical Research Center",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100350679","cloud-r-hae-registry-100350679","NCT03845946","CLOUD-R HAE REGISTRY","International Registry of Isolated Angioedema","CloudRHAE","Inclusion Criteria:\n\n* Any patient with isolated angioedema without associated wheals.\n* Patients with hereditary angioedema with or without C1 deficiency.\n* Major patient with consent (signature)\n* Minor patient whose parents \u002F legal guardians have given their consent (signature)\n\nExclusion Criteria:\n\n* Patient unable to give consent.\n* Wheals with angioedema",{"count":120,"type":20},1000,"5 Years","OBSERVATIONAL","Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and\u002For gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. But there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. These angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. Being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. This registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.",[125],"ANGIOEDEMA","2021-10-29",{"date":128,"type":45},"2021-11-01",{"date":130,"type":45},"2018-09-01",{"date":132,"type":20},"2028-09-01",{"name":134,"class":52},"University Hospital, Grenoble"]